SAN DIEGO, March 20, 2012 /PRNewswire/ -- HUYA Bioscience International announced today a critical strategic partnership with one of China's preeminent pharmacological researchers, Prof. Deyong Ye of Fudan University's School of Pharmacy. HUYA is an international leader in supporting the global development of China's pharmaceutical innovations. Their new partnership with Fudan University will focus on specific innovations coming out of Prof. Deyong Ye's lab that could meet critical global pharmaceutical needs.
Prof. Ye is currently vice director of the Department of Medicinal Chemistry at the School of Pharmacy. His lab specializes in drug design and synthesis, including computer modeling of the three dimensional structures of enzymes such as sphingomyelin synthase (SMS). Using those structures, the lab is designing drugs that will work as SMS inhibitors to target and combat diseases, including metabolic disease and cardiovascular disease. The lab has been awarded multiple grants in this field and is at the forefront of China's efforts to promote innovative drug design.
The new partnership between HUYA and Prof. Ye's lab will enable both parties to collaborate to promote new drug development in China and worldwide. The lab will be able to consult with HUYA's wide range of experts in drug development and globalization. In turn, HUYA will have the first opportunity to evaluate certain research and development projects conducted at the lab, and will provide support and assistance as needed.
"Working with labs such as Prof. Deyong Ye's puts us at the cutting edge of drug innovation and development in China," said Clement Gingras, HUYA's Chief Technical Officer and COO, "We are honored by this opportunity and look forward to beneficial collaborations in the years to come."
In Shanghai, Prof. Ye says he also welcomes this new partnership and is optimistic about its results: